Breast Cancer Clinical Trials in Tampa, Florida

22 studies are recruiting for breast cancer in Tampa, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

    The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Locations
    567 in total
    Run by
    Stemline Therapeutics, Inc.

    See if you can join NCT06492616 on ClinicalTrials.gov

  2. Evaluation and Outcomes of SAVI Scout MD for Localized Breast Surgery

    The purpose of the study is to evaluate how precise the SAVI Scout MD is and how easy it is for surgeons to use during surgery. The SAVI Scout MD system uses tiny radar reflectors instead of wires, can be placed days or weeks before surgery, helps surgeons find the cancer more precisely and may low…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Run by
    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT07686250 on ClinicalTrials.gov

  3. A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

    The purpose of this study is to assess the safety of GDC-4198 alone and in combination with giredestrant and also the efficacy of GDC-4198 + giredestrant versus abemaciclib + giredestrant in participants with locally advanced or metastatic ER+, HER2- breast cancer. The study consists of 2 phases: P…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Locations
    64 in total
    Run by
    Genentech, Inc.

    See if you can join NCT07100106 on ClinicalTrials.gov

  4. A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

    This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participants with endocrine-sensitive PIK3CA-mutated hormone receptor-p…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Moffitt Cancer Center-McKinley Campus, Tampa, Florida
    Locations
    241 in total
    Run by
    Hoffmann-La Roche

    See if you can join NCT06790693 on ClinicalTrials.gov

  5. A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

    Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Research Site, Tampa, Florida
    Locations
    23 in total
    Run by
    AstraZeneca

    See if you can join NCT05877599 on ClinicalTrials.gov

  6. Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

    This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Clinical Trial Site, Tampa, Florida
    Locations
    181 in total
    Run by
    Olema Pharmaceuticals, Inc.

    See if you can join NCT07085767 on ClinicalTrials.gov

  7. FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

    This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of RGT-419B administered orally as monotherapy OR in combination with Hormonal Therapy in subjects with HR+, HER2- locally advanced and unresectable…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Locations
    8 in total
    Run by
    Regor Pharmaceuticals Inc.

    See if you can join NCT05304962 on ClinicalTrials.gov

  8. Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

    This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have completed both neoadjuvant and postoperative adjuvant standard of car…

    Stage
    Phase 3
    Ages
    18 to 100
    Site
    Moffitt Cancer Center, Tampa, Florida
    Locations
    179 in total
    Run by
    Greenwich LifeSciences, Inc.

    See if you can join NCT05232916 on ClinicalTrials.gov

  9. Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD

    The purpose of this study is to learn about the effects of the study treatment, Dendritic Cell Vaccine (DCV), in combination with trastuzumab or nivolumab to confirm the highest dose of the study treatment that can be given safely to participants with Breast Cancer (BC) with Leptomeningeal Disease …

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Run by
    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT07694986 on ClinicalTrials.gov

  10. First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

    Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with P13Ka mutations. Part 1 will evaluate STX-478 as monotherap…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Locations
    65 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT05768139 on ClinicalTrials.gov

  11. Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer

    The purpose of the study is to determine the frequency of systemic metastasis in node positive breast cancer following chemotherapy and surgery. Participants will be asked to spend about 6 months in this study. Participants will undergo a computed tomography (CT) screening of the thorax, abdomen, a…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Run by
    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT06833502 on ClinicalTrials.gov

  12. A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

    A Study of Emi-Le in Participants with Solid Tumors

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Locations
    26 in total
    Run by
    Day One Biopharmaceuticals, Inc.

    See if you can join NCT05377996 on ClinicalTrials.gov

  13. Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

    This study will evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) 0 (who are both hormone receptor [HR]-negative and HR-positive) unresectable and/or metastatic breast cancer.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    USF College of Medicine, Tampa, Florida
    Locations
    88 in total
    Run by
    Daiichi Sankyo

    See if you can join NCT05950945 on ClinicalTrials.gov

  14. Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer

    This randomized, multi-institutional phase III trial evaluates whether routine surveillance brain MRI every 6 months improves detection and treatment characteristics of brain metastases in neurologically asymptomatic patients with stage IV breast cancer. Patients are stratified by receptor subtype,…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Locations
    2 in total
    Run by
    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT07357298 on ClinicalTrials.gov

  15. I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic res…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    Locations
    42 in total
    Run by
    QuantumLeap Healthcare Collaborative

    See if you can join NCT01042379 on ClinicalTrials.gov

  16. Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy

    This is a pilot protocol to evaluate the safety, feasibility, and immunogenicity of a personalized breast cancer vaccine based utilizing whole exome sequencing data of a patient's residual breast tumor following neoadjuvant chemotherapy.

    Stage
    EARLY_Phase 1
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Run by
    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT06435351 on ClinicalTrials.gov

  17. The MIND-BC Study: MIND Diet for Breast Cancer Cognition

    This fully, powered efficacy RCT, the MIND diet for Breast Cancer Cognition (MIND-BC), will evaluate the MIND diet in a rigorous, highly controlled academic cancer center. We will recruit breast cancer survivors reporting CRCI with a MIND diet score < 8, based on a previously devised 14-item diet q…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Run by
    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT07018986 on ClinicalTrials.gov

  18. EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

    The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.

    Stage
    Not phased
    Ages
    18 and older
    Site
    St. Joseph's Women's Hospital, Tampa, Florida
    Locations
    58 in total
    Run by
    Exact Sciences Corporation

    See if you can join NCT06401421 on ClinicalTrials.gov

  19. Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

    This is a Phase I/II Study to determine the safety and efficacy of Sacituzumab Govitecan and Zimberelimab with stereotactic radiation (SRS) in participants with metastatic triple negative breast cancer with brain metastases, compared to treatment with Sacituzumab Govitecan alone.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Run by
    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT06238921 on ClinicalTrials.gov

  20. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Tampa, Florida
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

  21. MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

    The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enabl…

    Stage
    Not phased
    Ages
    18 and older
    Site
    St. Joseph's Hospital - Baycare, Tampa, Florida
    Locations
    134 in total
    Run by
    Agendia

    See if you can join NCT03053193 on ClinicalTrials.gov

  22. A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

    This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with capecitabine (Cap) vs. standard dose of Cap alone in patients with advanced or metastatic breast cancer. The goal of the study is to assess the efficacy and safety of PCS6422 + Cap as…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Locations
    13 in total
    Run by
    Processa Pharmaceuticals

    See if you can join NCT06568692 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.